QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)

Beximco Pharmaceuticals (BXP) Competitors

GBX 36.60
+0.10 (+0.27%)
(As of 01:40 PM ET)

BXP vs. AGY, ANCR, APH, EAH, CEL, VLG, BMK, CREO, AVCT, and HVO

Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Allergy Therapeutics (AGY), Animalcare Group (ANCR), Alliance Pharma (APH), ECO Animal Health Group (EAH), Celadon Pharmaceuticals (CEL), Venture Life Group (VLG), Benchmark (BMK), Creo Medical Group (CREO), Avacta Group (AVCT), and hVIVO (HVO). These companies are all part of the "medical" sector.

Beximco Pharmaceuticals vs.

Beximco Pharmaceuticals (LON:BXP) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.

Beximco Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Beximco Pharmaceuticals has a net margin of 11.80% compared to Allergy Therapeutics' net margin of -72.28%. Beximco Pharmaceuticals' return on equity of 10.29% beat Allergy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals11.80% 10.29% 6.55%
Allergy Therapeutics -72.28%-216.27%-31.48%

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Allergy Therapeutics Neutral

1.6% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Allergy Therapeutics shares are held by institutional investors. 93.2% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£41.65B0.00£4.92B£0.08457.50
Allergy Therapeutics£59.59M2.28-£43.07M-£0.06-47.50

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Allergy Therapeutics received 253 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 77.97% of users gave Allergy Therapeutics an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Beximco PharmaceuticalsOutperform Votes
108
64.67%
Underperform Votes
59
35.33%
Allergy TherapeuticsOutperform Votes
361
77.97%
Underperform Votes
102
22.03%

Summary

Beximco Pharmaceuticals beats Allergy Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

MetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£163.28M£1.04B£4.76B£1.38B
Dividend Yield6.45%3.04%2.98%11.65%
P/E Ratio457.501,250.70226.821,740.55
Price / Sales0.0010,081.442,318.97342,411.65
Price / CashN/A26.4046.8532.99
Price / BookN/A3.204.582.50
Net Income£4.92B£92.61M£104.17M£182.76M
7 Day Performance0.27%-1.63%-5.27%-0.41%
1 Month Performance-1.74%4.27%-4.85%7.60%
1 Year Performance-12.44%19.28%8.59%16.60%

Beximco Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
0 of 5 stars
GBX 2.85
flat
N/AN/A£135.95M£59.59M-47.50612Gap Up
High Trading Volume
ANCR
Animalcare Group
0 of 5 stars
GBX 210
flat
N/A+13.0%£126.23M£70.04M10,500.00220
APH
Alliance Pharma
3.0545 of 5 stars
GBX 37.05
+0.4%
GBX 80.75
+117.9%
-39.1%£200.22M£170.05M-3,705.00285News Coverage
EAH
ECO Animal Health Group
0 of 5 stars
GBX 93.50
-1.1%
N/A-7.6%£63.34M£88.46M-4,675.00234
CEL
Celadon Pharmaceuticals
0 of 5 stars
GBX 87.50
flat
GBX 222.50
+154.3%
-33.3%£56.18M£11,258.00-673.0824Gap Up
VLG
Venture Life Group
0 of 5 stars
GBX 37.25
-2.0%
N/A-10.6%£47.12M£48.57M-3,725.00153Gap Down
High Trading Volume
BMK
Benchmark
0 of 5 stars
GBX 43.80
-1.5%
N/A+14.5%£323.92M£155.53M-1,460.00823
CREO
Creo Medical Group
0 of 5 stars
GBX 37.75
-3.2%
N/A+30.2%£136.46M£29.27M-343.18279Positive News
AVCT
Avacta Group
0 of 5 stars
GBX 54
+0.5%
N/A-64.0%£189.28M£16.02M-337.50120
HVO
hVIVO
0 of 5 stars
GBX 29
+0.7%
N/A+75.0%£197.31M£60.48M-1.00N/ANews Coverage

Related Companies and Tools

This page (LON:BXP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners